

NCT02965443 Raw comparison:

Summary:
CHIA has 32 criteria while your personal folder has 37 criteria
Total found criteria: 32/32
Total not Found: 0/32
Total Extra: 5
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Type 2 diabetes                                    │ Type 2 diabetes                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age 18 - 75 years                                  │ Age 18 - 75 years                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Anti-GAD antibodies negative (Glutamic Acid        │ Anti-GAD antibodies negative (Glutamic Acid        │
│ Decarboxylase)                                     │ Decarboxylase)                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ C-peptide levels = 1 5 ng/mL                       │ C-peptide levels ≥ 1 5 ng/mL                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fasting blood glucose > 126 mg/dl                  │ Fasting blood glucose \> 126 mg/dl                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HbA1c 8 0 - 10 5 %                                 │ HbA1c 8 0 - 10 5 %                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ BMI 25 0 - 45 0 kg/m2                              │ BMI 25 0 - 45 0 kg/m2                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous therapy with BBIT (basal insulin and at   │ Previous therapy with BBIT (basal insulin and at   │
│ least once daily bolus insulin)                    │ least once daily bolus insulin)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any oral antidiabetic treatment except for  │ Use of any oral antidiabetic treatment except for  │
│ metformin (i e sulphonylureas DPP-IV inhibitors    │ metformin (i e sulphonylureas DPP-IV inhibitors    │
│ thiazolidinediones SGLT-2 inhibitors (Sodium       │ thiazolidinediones SGLT-2 inhibitors (Sodium       │
│ dependent glucose transporter) or GLP-1 analogues  │ dependent glucose transporter) or GLP-1 analogues  │
│ (glucagone like peptide) within the last three     │ (glucagone like peptide) within the last three     │
│ months prior to Screening                          │ months prior to Screening                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Repeated episodes of severe hypoglycaemia within   │ Repeated episodes of severe hypoglycaemia within   │
│ the last six months prior to Screening             │ the last six months prior to Screening             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of diabetic ketoacidosis precoma diabetica │ History of diabetic ketoacidosis precoma diabetica │
│ or diabetic coma                                   │ or diabetic coma                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with any other investigational drug      │ Treatment with any other investigational drug      │
│ within the last three months before Screening      │ within the last three months before Screening      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute infections within the last four weeks prior  │ Acute infections within the last four weeks prior  │
│ to Screening                                       │ to Screening                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Recurrent urogenital infections                    │ Recurrent urogenital infections                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of pancreatitis                            │ History of pancreatitis                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Anamnestic history of hypersensitivity to the      │ Anamnestic history of hypersensitivity to the      │
│ study drugs or to drugs with similar chemical      │ study drugs or to drugs with similar chemical      │
│ structures                                         │ structures                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of severe or multiple allergies            │ History of severe or multiple allergies            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant participation in other clinical trials │ Concomitant participation in other clinical trials │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Type 1 diabetes                                    │ Type 1 diabetes                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cardiovascular disease Clinically relevant         │ Cardiovascular disease Clinically relevant         │
│ ventricular tachycardia or ventricular             │ ventricular tachycardia or ventricular             │
│ fibrillation 3rd degree AV block or Torsades de    │ fibrillation 3rd degree AV block or Torsades de    │
│ Pointes or treatment with antiarrhythmic drugs     │ Pointes or treatment with antiarrhythmic drugs     │
│ Percutaneous coronary intervention within the past │ Percutaneous coronary intervention within the past │
│ 6 months Any of the following within the past 6    │ 6 months Any of the following within the past 6    │
│ months myocardial infarction (MI) coronary artery  │ months myocardial infarction (MI) coronary artery  │
│ bypass surgery unstable angina or stroke           │ bypass surgery unstable angina or stroke           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Malignancy including leukemia and lymphoma within  │ Malignancy including leukemia and lymphoma within  │
│ the last 5y                                        │ the last 5y                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Liver disease such as cirrhosis or chronic active  │ Liver disease such as cirrhosis or chronic active  │
│ hepatitis                                          │ hepatitis                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant renal dysfunction (see also exclusion  │ Significant renal dysfunction (see also exclusion  │
│ criteria laboratory abnormalities)                 │ criteria laboratory abnormalities)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ State after kidney transplantation                 │ State after kidney transplantation                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Endocrine disease                                  │ Endocrine disease                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Systolic blood pressure outside the range of       │ Systolic blood pressure outside the range of       │
│ 100-160 mmHg or diastolic blood pressure above 95  │ 100-160 mmHg or diastolic blood pressure above 95  │
│ mmHg at Screening                                  │ mmHg at Screening                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of active substance abuse (including       │ History of active substance abuse (including       │
│ alcohol > 40g/day) within the past 2 years         │ alcohol \> 40g/day) within the past 2 years        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy or childbearing potential without        │ Pregnancy or childbearing potential without        │
│ adequate contraception                             │ adequate contraception                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Present therapy with systemic steroids             │ Present therapy with systemic steroids             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of psychiatric disorder or intake of      │ Presence of psychiatric disorder or intake of      │
│ anti-depressive or anti-psychotic agents with the  │ anti-depressive or anti-psychotic agents with the  │
│ exception of benzodiazepines and SSRIs/SNRI's      │ exception of benzodiazepines and SSRIs/SNRI´s      │
│ (selective serotonin reuptake inhibitor)           │ (selective serotonin reuptake inhibitor)           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Potentially unreliable subjects and those judged   │ Potentially unreliable subjects and those judged   │
│ by the investigator to be unsuitable for the study │ by the investigator to be unsuitable for the study │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindications for Magnetic resonance (MR)      │ Contraindications for Magnetic resonance (MR)      │
│ scanning such as persons with cardiac pacemaker    │ scanning such as persons with cardiac pacemaker    │
│ and implants out of metal or claustrophobia        │ and implants out of metal or claustrophobia        │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Uncontrolled unstable angina pectoris or history of pericarditis myocarditis endocarditis Congestive │
│ heart failure NYHA (New York Heart Association) class III or IV Increased risk of thromboembolism e  │
│ g subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis  │
│ as judged by the Investigator                                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 75 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ •Any of the following significant laboratory abnormalities eGFR (as calculated by the MDRD equation) │
│ \< 60 ml/min at Screening Fasting triglycerides \>700 mg/dl (\>7 9 mmol/l)                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Acromegaly or treatment with growth hormone or similar drugs Chronic oral or parenteral              │
│ corticosteroid treatment (\>7 consecutive days of treatment) within 8 weeks thyroid hormone          │
│ replacement is allowed if the dosage has been stable for at least 3 months and the TSH is within     │
│ normal limits                                                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛